184 related articles for article (PubMed ID: 9715509)
1. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice.
Mahler JF; Flagler ND; Malarkey DE; Mann PC; Haseman JK; Eastin W
Toxicol Pathol; 1998; 26(4):501-11. PubMed ID: 9715509
[TBL] [Abstract][Full Text] [Related]
2. The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens.
Eastin WC; Haseman JK; Mahler JF; Bucher JR
Toxicol Pathol; 1998; 26(4):461-73. PubMed ID: 9715504
[TBL] [Abstract][Full Text] [Related]
3. Oxymetholone: III. Evaluation in the p53+/- transgenic mouse model.
Stoll RE; Holden HE; Barthel CH; Blanchard KT
Toxicol Pathol; 1999; 27(5):513-8. PubMed ID: 10528630
[TBL] [Abstract][Full Text] [Related]
4. Genetically altered mouse models for identifying carcinogens.
Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
[No Abstract] [Full Text] [Related]
5. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
6. P53+/- hemizygous knockout mouse: overview of available data.
Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
[TBL] [Abstract][Full Text] [Related]
7. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
Cohen SM
Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
[TBL] [Abstract][Full Text] [Related]
8. Tg.AC genetically altered mouse: assay working group overview of available data.
Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
[TBL] [Abstract][Full Text] [Related]
9. Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin tumors in Tg.AC mice.
Spalding JW; French JE; Tice RR; Furedi-Machacek M; Haseman JK; Tennant RW
Toxicol Sci; 1999 Jun; 49(2):241-54. PubMed ID: 10416269
[TBL] [Abstract][Full Text] [Related]
10. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens.
Tennant RW; Spalding J; French JE
Mutat Res; 1996 Sep; 365(1-3):119-27. PubMed ID: 8898993
[TBL] [Abstract][Full Text] [Related]
12. The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists.
Floyd E; Mann P; Long G; Ochoa R
Toxicol Pathol; 2002; 30(1):147-56. PubMed ID: 11890468
[TBL] [Abstract][Full Text] [Related]
13. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
French J; Storer RD; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
[TBL] [Abstract][Full Text] [Related]
14. The U.S. National Toxicology Program evaluation of transgenic mice as predictive models for identifying carcinogens.
Eastin WC
Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):81-4. PubMed ID: 9539007
[TBL] [Abstract][Full Text] [Related]
15. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.
Takaoka M; Sehata S; Maejima T; Imai T; Torii M; Satoh H; Toyosawa K; Tanakamaru ZY; Adachi T; Hisada S; Ueda M; Ogasawara H; Matsumoto M; Kobayashi K; Mutai M; Usui T
Toxicol Pathol; 2003; 31(2):191-9. PubMed ID: 12696579
[TBL] [Abstract][Full Text] [Related]
16. Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens.
Holden HE; Stoll RE; Blanchard KT
Toxicol Pathol; 1999; 27(5):507-12. PubMed ID: 10528629
[TBL] [Abstract][Full Text] [Related]
17. Carcinogenic responses of transgenic heterozygous p53 knockout mice to inhaled 239PuO2 or metallic beryllium.
Finch GL; March TH; Hahn FF; Barr EB; Belinsky SA; Hoover MD; Lechner JF; Nikula KJ; Hobbs CH
Toxicol Pathol; 1998; 26(4):484-91. PubMed ID: 9715507
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype.
Weaver JL; Contrera JF; Rosenzweig BA; Thompson KL; Faustino PJ; Strong JM; Ellison CD; Anderson LW; Prasanna HR; Long-Bradley PE; Lin KK; Zhang J; Sistare FD
Toxicol Pathol; 1998; 26(4):532-40. PubMed ID: 9715512
[TBL] [Abstract][Full Text] [Related]
19. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
Mitsumori K; Koizumi H; Nomura T; Yamamoto S
Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
[TBL] [Abstract][Full Text] [Related]
20. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.
Venkatachalam S; Tyner SD; Pickering CR; Boley S; Recio L; French JE; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():147-54. PubMed ID: 11695551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]